Companies · Other Health Care
LOS ANGELES · Other Health Care
Diligence memoA one-page analyst read on Pharmaco-Kinesis Corp — recommendation, valuation, rhythm, risks.→Pharmaco-Kinesis Corp looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Pharmaco-Kinesis Corp is one of 5377 Other Health Care companies tracked from LOS ANGELES. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 82% of sector peers (real $). Modeled value above 58% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #18 of 19.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Medical Imaging Holdings, Inc. | Series B | $39.9M | $885.1M | 1.87× |
| ev3 Inc. | Series B | $34.6M | $767.6M | 1.62× |
| Avalign Technologies Holdings, Inc. | Series B | $31.4M | $694.5M | 1.47× |
| GEMCare Mercy Memorial Health System LLC | Series B | $29.0M | $642.5M | 1.36× |
| Metagenics, Inc. | Series B | $28.1M | $622.5M | 1.32× |
| Satiety Inc | Series B | $34.3M | $559.9M | 1.18× |
| IZI Medical Products LLC | Series B | $22.7M | $502.6M | 1.06× |
| Payformance Holding Corp | Series B | $22.3M | $493.1M | 1.04× |
| Candescent Healing LLC | Series B | $21.5M | $476.6M | 1.01× |
| Walnut Hill Physicians' Hospital, LLC | Series B | $21.3M | $472.9M | 1.00× |
| Interlace Medical Inc | Series B | $20.5M | $454.2M | 0.96× |
| Sleep Solutions Inc | Series B | $20.0M | $443.1M | 0.94× |
| Pharmaco-Kinesis Corp this company | Series B | $17.2M | $30.8M | 0.07× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.2M | 2008-09-18 | $6.2M | $30.8M | 90% |
| Series B | $16.0M | — | $88.9M | $56.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Eli Gang | — | 4 other | 2008-09 |
| Frank Adell | — | 4 other | — |
| Josh Shachar | — | 4 other | 2008-09 |
| Thomas Chen | — | 4 other | 2008-09 |
| Daniel Saks | — | 3 other | 2008-09 |
| Ronald Solar | — | 2 other | 2008-09 |
| Daniel Hilton | — | 1 other | 2008-09 |
| Jeremy Ruskin | — | 1 other | 2008-09 |
| Thomas Chen, M.D., Ph.D. | — | 1 other | — |
| Eli Gang, M.D. | — | — | — |
| Farokh Adelzadeh | — | — | 2008-09 |
| Gregg Pollack | — | — | — |
| Guigio Lenaz | — | — | 2008-09 |
| Jain Mudit, Ph.D. | — | — | — |
| Jeremy Ruskin, M.D. | — | — | — |
| John Matheu | — | — | 2008-09 |
| Lili Xie, Ph.D. | — | — | — |
| Mehdi Hatamian | — | — | 2008-09 |
| Mehdi Hatamian, Ph.D. | — | — | — |
| Mike Moshayedi | — | — | — |
| Peter Hirschfield | — | — | 2008-09 |
| Peter Hirshfield, Esq. | — | — | — |
| Philippe Gadal, Ph.D. | — | — | — |
| Ronald Solar, Ph.D. | — | — | — |
Pharmaco-Kinesis Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Cognos Therapeutics Inc | Biotechnology | Series C | $7.7M | $44.2M | network5 shared operators |
| Magnetecs Corp | Other Health Care | Series A | $19.8M | $88.1M | network3 shared operators · same sector |
| Autonomous Medical Devices Inc | Healthtech | Series D+ | $142.4M | $2.8B | network5 shared operators |
| Neuro-Kinesis Corp | Biotechnology | Pre-Seed | $400K | $11.9M | network3 shared operators |
| ReliantHeart Inc. | Other Health Care | Series B | $20.1M | $32.2M | same sector · same stage |
| Abs Topco, Llc | Other Health Care | Series B | $25.5M | $34.2M | same sector · same stage |
| China Horizon Investments Group | Retailing | Series B | $19.7M | $2.0M | network1 shared operator · same stage |
| Neonc Technologies, Inc. | Pharmaceuticals | Series B | $20.1M | $680.1M | network1 shared operator · same stage |
See where Pharmaco-Kinesis Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Pharmaco-Kinesis Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.